InvestorsHub Logo
Followers 5
Posts 213
Boards Moderated 0
Alias Born 08/19/2013

Re: chrisand813 post# 374

Tuesday, 11/12/2013 12:00:35 PM

Tuesday, November 12, 2013 12:00:35 PM

Post# of 3835
Back down to $8.0. Looks like we are going the wrong way.


----------------------------------------------------------------------------------------
"We are pleased to announce completion of enrollment of the first five of eight patients in our Phase 1 clinical trial for patients with NASH (fatty liver disease) with advanced fibrosis. The patients enrolled have not incurred any serious adverse events. Completion of the enrollment of the first cohort will be an important milestone in the development of our proprietary, novel technology and, if all goes as expected, the clinical data from the first cohort should be available early in 2014," said Peter G. Traber, M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics. "This Phase 1 first-in-man study will evaluate the safety, tolerability, pharmacokinetics and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 when administered to patients with fatty liver disease with advanced fibrosis."
---------------------------------------------------------------------------------------

One would think we would have went up today on this 10Q

I will take advantage and pick up some more GALTW


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News